Enanta Pharmaceuticals Inc at JMP Securities Life Sciences Virtual Conference Transcript
All right. Well, thanks, everyone, for joining us again for the JMP Securities life sciences conference. My name is Roy Buchanan. I'm on the biotech team, on the research side. And the next company we have is Enanta Pharmaceuticals. We cover it with a market outperform rating. And we have Jay Luly, the President and CEO of Enanta. Enanta is almost solely focused on small molecule treatments for important viral pathogens, and they've successfully developed one of the components of AbbVie's approved hepatitis C drug, MAVYRET.
So I'm not sure, Jay, if you wanted to give a quick intro to Enanta, or we can just dive into the questions?
Yes, maybe just a very, very brief intro. And before I begin, I want to remind people I will be making some forward-looking statements today. And for a summary of the risks associated with these statements, please see our filings on SEC.gov and on our website.
Yes, so for those less familiar, Enanta is a drug
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |